Bloomberg Knowledge experts stated Roctavian’s sluggish launch “stands for a substantial overhang for BioMarin.
发布者：BY MIKKEL AABENHUS HEMMINGSEN，转转请注明出处：https://robotalks.cn/biomarin-trims-spending-on-fizzling-gene-therapy/
BioMarin trims spending on fizzling gene therapy
赞 (0)
关于作者
Sonova launches two new platforms and AI-powered premium product
上一篇
12 8 月, 2024 4:17 下午
Novo Nordisk expected to upgrade guidance after double-digit growth in the first half
下一篇
12 8 月, 2024 4:18 下午
相关推荐
-
Analyst: Good news for potential Wegovy successor could spark comeback for Novo stock
Given that the rate document in June, Novo Nordisk’s share rate has actually come by 23%.
-
US UoM Consumer Confidence Index rises to 70.1 in September
Customer self-confidence in the United States boosted in September, with the College of Michigan’s Customer View Index bordering greater to 70.1 from 66 in August …Read…
-
RELYCO Approved to Provide Durable REVLAR Material for New Jersey Temporary License Plates
RELYCO is enjoyed introduce that its ingenious REVLAR product has actually been authorized by the New Jacket Automobile Payment for usage in the state’s momentary certificate…
-
STM Online Services Report 2024-2028, with Key Company Profiles for American Chemical Society, Athenahealth, CGG, Clarivate, EBSCO, Elsevier, Hearst Health, Merative, S&P Global and Wolters Kluwer – ResearchAndMarkets.com
DUBLIN–( COMPANY CABLE)– The “Worldwide STM Online Solutions, 2024-2028” record has actually been contributed to ResearchAndMarkets.com’s offering. Th…
